Avutometinib clinical trials
Avutometinib is named as an intervention in 5 current clinical trials in our France, UK, USA, Spain, Italy, Belgium, Canada, Japan, Mexico, Ireland, Germany, Netherlands, Denmark, Poland, South Korea and Australia registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Verastem, Inc (4). The most-studied condition is Ovarian Cancer.
Where Avutometinib is approved
All regulators →- 1 EU orphan designation, most recently for treatment of ovarian cancer (18 Jul 2025, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Avutometinib works
All drug targets →- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor InhibitorTarget: MAP2K1 mitogen-activated protein kinase kinase 1✓ In ChEMBL and the Guide to Pharmacology
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor InhibitorTarget: MAP2K2 mitogen-activated protein kinase kinase 2ChEMBL only
- Colorectal cancerPhase 2
- Differentiated thyroid carcinomaPhase 2
- Female reproductive system neoplasmPhase 2
- Gastric cancerPhase 2
- Gastric neoplasmPhase 2
- Lung adenocarcinomaPhase 2
- Mucinous ovarian cancerPhase 2
- Non-small cell lung carcinomaPhase 2
- Ovarian cancerPhase 2
- Ovarian serous adenocarcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3264002, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11867, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Avutometinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Avutometinib
- ChEMBL
- CHEMBL3264002
- DrugBank
- DB15254
- PubChem CID
- 16719221
- FDA UNII
- D0D4252V97
- Wikidata
- Q27147976
- Wikipedia
- Avutometinib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Avutometinib
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Avutometinib
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Verastem, Inc | 4 |
| University of Oklahoma | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Avutometinib trials
How many clinical trials are testing Avutometinib?
5 current trials in our France, UK, USA, Spain, Italy, Belgium, Canada, Japan, Mexico, Ireland, Germany, Netherlands, Denmark, Poland, South Korea and Australia registers name Avutometinib (also registered as Avutometinib (VS-6766)) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Avutometinib trials recruiting patients?
Yes. 2 of the 5 trials are recruiting: 1 with sites in France, 1 with sites in UK, 1 with sites in USA, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Canada, 1 with sites in Japan, 1 with sites in Mexico, 1 with sites in Ireland, 1 with sites in Germany, 1 with sites in Netherlands, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in South Korea and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Avutometinib clinical trials?
Verastem, Inc (4) and University of Oklahoma (1). The number in brackets is how many trials each organisation leads.
Are there Avutometinib clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Avutometinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Avutometinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Avutometinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.